Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2002

01-10-2002 | Original Article

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

Authors: Thomas A. Puchalski, David P. Ryan, Rocio Garcia-Carbonero, George D. Demetri, Leah Butkiewicz, David Harmon, Michael V. Seiden, Robert G. Maki, Luis Lopez-Lazaro, Jose Jimeno, Cecilia Guzman, Jeffrey G. Supko

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2002

Login to get access
Metadata
Title
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity
Authors
Thomas A. Puchalski
David P. Ryan
Rocio Garcia-Carbonero
George D. Demetri
Leah Butkiewicz
David Harmon
Michael V. Seiden
Robert G. Maki
Luis Lopez-Lazaro
Jose Jimeno
Cecilia Guzman
Jeffrey G. Supko
Publication date
01-10-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0498-3

Other articles of this Issue 4/2002

Cancer Chemotherapy and Pharmacology 4/2002 Go to the issue

Original Article

Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat

Erratum

Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles

Original Article

Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens

Original Article

Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed

Original Article

Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats

Original Article

Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits